August 20, 2026

National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
Mumbai - 400 051
Symbol: LUPIN

BSE Limited
P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
Mumbai - 400 001
Scrip Code: Equity - 500257

Subject: **Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations")**

Dear Sir/Madam,

Pursuant to Regulation 30 read with Schedule III of the SEBI Listing Regulations, we wish to inform that VISUfarma B.V., the Netherlands, a wholly owned subsidiary of the Company, has entered into an Exclusive License Agreement with Visus Therapeutics, Inc. U.S.A., to commercialize YUVEZZI™, a proprietary ophthalmic product indicated for the treatment of Presbyopia in adults, in the European Union, the United Kingdom, Switzerland, Norway and Iceland.

The details required under Regulation 30 read with Schedule III of the SEBI Listing Regulations and the SEBI Master Circular dated January 30, 2026 (reference no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026), along with other applicable circulars, are set out in **Annexure I.**

A press release regarding this arrangement is enclosed herewith.

You are requested to kindly take the above on record.

For LUPIN LIMITED

AMIT KUMAR GUPTA

Digitally signed by AMIT KUMAR GUPTA
DN: c=IN, st=Maharashtra, 2.5.4.20=f72cf02f52d2a7e595b45b84659bdca28c8f26a939bb35835a169f2a237229a3, postalCode=400705, street=C701 Shivdarshan CHS Ltd Sector16 Plot No5 Navi Mumbai, pseudonym=d3a468d0d03546efabffd2a7cb7aaaae, title=7875, serialNumber=de9bbd80d8994e4be9f0dd2399144eba7e782d70287df6aad1994f0b522fa08a, o=Personal, cn=AMIT KUMAR GUPTA
Date: 2026.08.20 10:34:25 +05'30'

AMIT KUMAR GUPTA
COMPANY SECRETARY & COMPLIANCE OFFICER
(ACS -15754)

Encl.: a/a.

Annexure I

Disclosure as per Regulation 30 of SEBI Listing Regulations read with SEBI Master Circular.

Sr. No.	Particulars	Details
1.	Name of the entity(ies) with whom agreement~~/JV~~ is signed	Visus Therapeutics, Inc., a Delaware corporation in U.S.A. ('Visus') and VISUfarma B.V., the Netherlands, a wholly owned subsidiary of the Company ('VISUfarma').
2.	Area of agreement~~/JV~~	Exclusive License and Commercialization rights for YUVEZZI™ in the European Union, the United Kingdom, Switzerland, Norway and Iceland ('Licensed Territories').
3.	Domestic/international	Across European Union, the United Kingdom, Switzerland, Norway and Iceland.
4.	Share exchange ratio~~/JV ratio~~	Not applicable.
5.	Scope of business operation of agreement~~/JV~~	Exclusive rights to undertake regulatory activities, commercialization, marketing, promotion, distribution and sale of YUVEZZI™ in the Licensed Territories. The Agreement is valid on a country-by-country basis in the Licensed Territories and will continue until the twentieth (20th) anniversary of the date of the first commercial sale of YUVEZZI™ in the respective country ('Initial Term'), subject to earlier termination in accordance with the terms of the Agreement. After the Initial Term, VISUfarma, at its sole discretion, will have the right to renew the Agreement in such country for one or more additional successive periods of five (5) years each.
6.	Details of consideration paid/ ~~received in agreement/JV~~	The total potential consideration under the agreement is up to €75 million through to first commercial sales in the Territory, comprising (i) a €20 million strategic investment in the capital stock of Visus or its parent entity through a SAFE (Simple Agreement for Future Equity) instrument, which provides the right to receive capital stock of Visus or its parent entity upon the occurrence of specified equity financing or public listing events, and (ii) up to €55 million in regulatory and commercial milestone payments. In addition, the agreement provides for royalty payments based on net sales and sales milestone payments upon achievement of specified sales thresholds in the Licensed Territories, in accordance with the terms of the agreement.

LUPIN

		The milestone payments are contingent upon achievement of specified regulatory submissions, approvals and other commercial milestones in respect of YUVEZZI™ in the Licensed Territories.
7.	Significant terms and conditions of agreement~~/JV~~ in brief	Same as stated in point (5) and (6) above.
8.	Whether the acquisition would fall within related party transactions and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	The transaction does not fall within the ambit of related party transaction. None of the promoter/promoter group/group companies have any interest in the arrangement.
9.	Size of the entity~~(ies)~~	Visus is a biopharmaceutical company focused on developing eyecare drugs to rejuvenate vision in the aging eye, affiliated with Tenpoint Therapeutics Holding Limited through a parent holding company structure. Visus lead commercial asset is YUVEZZI™, an FDA-approved treatment for Presbyopia.
10.	Rationale and benefit expected.	This exclusive commercialization rights for YUVEZZI™ in Europe will strengthen Lupin's ophthalmology portfolio, expand its Specialty Business presence and create long-term growth opportunities in the Presbyopia treatment market across the Licensed Territories.

BSE: 500257	NSE: LUPIN	REUTERS: LUPIN.BO	BLOOMBERG: LPCIN

Lupin and Tenpoint Therapeutics Announce Strategic Partnership to Commercialize YUVEZZI™ in the European Union, the United Kingdom, Switzerland, Norway, and Iceland

Demonstrates a shared commitment to extend global access for the only once-daily dual-agent presbyopia-correcting eye drop in the rapidly growing presbyopia vision management segment

Mumbai, India, Naples, FL, Netherlands, Amsterdam, London, UK, Warren, NJ, August 20, 2026: Global pharma major Lupin Limited ("Lupin") today announced that VISUfarma B.V. ("VISUfarma"), a wholly owned subsidiary of Lupin, has entered into an exclusive licensing agreement with Visus Therapeutics Inc., U.S.A., a wholly owned subsidiary of Tenpoint Therapeutics Holding Limited ("Tenpoint"). This partnership provides VISUfarma the exclusive rights to undertake regulatory activities, commercialization, marketing, promotion, distribution and sale of YUVEZZI™ (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1%, a proprietary ophthalmic product indicated for the treatment of presbyopia in adults, in the European Union, the United Kingdom, Switzerland, Norway and Iceland (Licensed Territories).

Under the agreement, VISUfarma will make a strategic investment in Visus. Tenpoint and Visus, individually or collectively, will also be eligible to receive regulatory and commercial milestone payments, as well as tiered royalties based on net sales.

Vinita Gupta, Chief Executive Officer, Lupin, said, "We are delighted to partner with Tenpoint Therapeutics to bring a novel ophthalmic therapy that advances our Specialty Care strategy. Building on the strategic acquisition of VISUfarma, this partnership further strengthens our vision care franchise and expands our presence across key European markets. The addition of YUVEZZI™ underscores our commitment to broadening access to differentiated therapies, improving patient outcomes, and reinforcing our leadership in eye care across the Licensed Territories."

"This exciting partnership marks an important step for Tenpoint as we continue our work to make YUVEZZI™ available for the millions of patients with presbyopia and eye care professionals around the world," said **Henric Bjarke, Chief Executive Officer, Tenpoint**. "Lupin's strong commercial operations span major European markets, and its specialty ophthalmology company VISUfarma's longstanding presence in eyecare makes them an excellent partner. We look forward to working together as we bring YUVEZZI™ to Europe."

As the first and only approved once-daily, dual-agent eye drop for presbyopia, YUVEZZI™ represents a significant advancement in eye care. The addition of YUVEZZI™ enhances Lupin's ophthalmology portfolio and supports the company's strategy for expanding its specialty care business through innovative therapies that address significant unmet patient needs.

Tenpoint is advancing commercialization of YUVEZZI™ in the United States following its recent U.S. FDA approval. This further expands the reach of YUVEZZI™ through strategic regional partnerships worldwide, and Tenpoint has already submitted an MMA in the UK, via the MHRA's International Recognition Procedure. It will continue to execute its plans for regulatory applications for YUVEZZI™ in other key regions worldwide.

About Lupin

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with a strong presence across India, the U.S., Other Developed Markets, and Emerging Markets, with products distributed in over 100 markets. Lupin has a diversified portfolio spanning generics, complex generics, specialty medicines, and biosimilars, and continues to strengthen its market position through a differentiated portfolio. The company maintains strong leadership in the U.S. and India across core therapeutic areas, including cardiovascular, respiratory, diabetes, gastrointestinal, and women's health. 15 state-of-the-art manufacturing facilities support sustainable operations, with 6 research centers and a dedicated workforce of over 26,000 professionals. Lupin continues to expand the healthcare ecosystem through diagnostics, digital health, patient-support programs, and disease management initiatives. Sustainability continues to be a core pillar of the company's business strategy.

To learn more, visit www.lupin.com or follow us on LinkedIn https://www.linkedin.com/company/lupin

About YUVEZZI™

YUVEZZI™ (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% is a once-daily, dual-agent eye drop approved by the U.S. Food & Drug Administration (FDA) for the treatment of presbyopia, a condition characterized by the gradual loss of near vision acuity that typically begins around age 45.

YUVEZZI combines two medicines that work together to improve close-up vision. Carbachol helps pupils get smaller (or "constrict"), making it easier to focus up close. Brimonidine helps keep pupils from getting too large (or "dilating").

For more information about YUVEZZI and full Prescribing Information, please visit www.YUVEZZI.com. Eye care professionals can visit www.YUVEZZIECP.com for additional resources.

YUVEZZI™ Important Safety Information

Do not use YUVEZZI if you are allergic to any of its ingredients or if you currently have inflammation of the iris (iritis).

Before taking YUVEZZI, tell your doctor if you have depression, low blood pressure, or circulation problems.

YUVEZZI may cause temporary blurry, dim, or dark vision. If you experience this, avoid driving, using machinery, and participating in hazardous activities. Use caution when night driving and in other activities in low light.

Call your doctor right away if you suddenly have flashes of light, floaters, or vision loss.

Do not let the tip of the vial touch your eye, eyelid, or any other surface.

The most common side effects of YUVEZZI are headache, impaired vision, and temporary eye pain and/or eye irritation upon use. These are not all of the possible side effects of YUVEZZI.

Most side effects were generally mild, didn't last long, and went away on their own.

About Tenpoint Therapeutics
Tenpoint Therapeutics Ltd. is a commercial-stage ophthalmic pharmaceutical company focused on the commercialization of YUVEZZI™ (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1%, the first and only dual-agent eye drop for the treatment of presbyopia, a condition that affects nearly 128 million people in the U.S. and approximately 2 billion people globally. By understanding real-world needs and partnering with eye care professionals, Tenpoint is working to bring innovation to the aging eye.

To learn more, visit https://tenpointtherapeutics.com/
Follow us https://www.linkedin.com/company/tenpointtherapeutics/

For further information or queries, please contact:

Media
Rajalakshmi Azariah
Vice President & Global Head – Corporate Communications, Lupin
rajalakshmiazariah@lupin.com

Brandi Robinson
media@tenpointtx.com

Eye Care Trade Media
Michele Gray
michele@mgraycommunications.com

Investors
Ami Bavishi or Nick Colangelo
Gilmartin Group LLC
tenpoint@gilmartinir.com